Cargando…
Aptamers Against COVID-19: An Untested Opportunity
Given the lack of success in the development of effective drugs to treat COVID-19, which show “game-changing” potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896377/ https://www.ncbi.nlm.nih.gov/pubmed/35023454 http://dx.doi.org/10.2174/1389557522666220112094951 |
_version_ | 1784882043189985280 |
---|---|
author | Haberland, Annekathrin Müller, Johannes |
author_facet | Haberland, Annekathrin Müller, Johannes |
author_sort | Haberland, Annekathrin |
collection | PubMed |
description | Given the lack of success in the development of effective drugs to treat COVID-19, which show “game-changing” potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is the case for direct antivirals and anti-inflammatory drugs, both of which treat different phases of the disease. Aptamers are molecules that deliver different modes of action, allowing their effects to be bundled, which, when combined, support their therapeutic efficacy. In this minireview, we summarise the current activities in the development of aptamers for the treatment of COVID-19 and long-COVID. A special emphasis is placed on the capability of their multiple modes of action, which is a promising approach for treating complex diseases such as COVID-19. |
format | Online Article Text |
id | pubmed-9896377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-98963772023-02-16 Aptamers Against COVID-19: An Untested Opportunity Haberland, Annekathrin Müller, Johannes Mini Rev Med Chem Pharmaceutical and Medicinal Chemistry Given the lack of success in the development of effective drugs to treat COVID-19, which show “game-changing” potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is the case for direct antivirals and anti-inflammatory drugs, both of which treat different phases of the disease. Aptamers are molecules that deliver different modes of action, allowing their effects to be bundled, which, when combined, support their therapeutic efficacy. In this minireview, we summarise the current activities in the development of aptamers for the treatment of COVID-19 and long-COVID. A special emphasis is placed on the capability of their multiple modes of action, which is a promising approach for treating complex diseases such as COVID-19. Bentham Science Publishers 2022 /pmc/articles/PMC9896377/ /pubmed/35023454 http://dx.doi.org/10.2174/1389557522666220112094951 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode |
spellingShingle | Pharmaceutical and Medicinal Chemistry Haberland, Annekathrin Müller, Johannes Aptamers Against COVID-19: An Untested Opportunity |
title | Aptamers Against COVID-19: An Untested Opportunity |
title_full | Aptamers Against COVID-19: An Untested Opportunity |
title_fullStr | Aptamers Against COVID-19: An Untested Opportunity |
title_full_unstemmed | Aptamers Against COVID-19: An Untested Opportunity |
title_short | Aptamers Against COVID-19: An Untested Opportunity |
title_sort | aptamers against covid-19: an untested opportunity |
topic | Pharmaceutical and Medicinal Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896377/ https://www.ncbi.nlm.nih.gov/pubmed/35023454 http://dx.doi.org/10.2174/1389557522666220112094951 |
work_keys_str_mv | AT haberlandannekathrin aptamersagainstcovid19anuntestedopportunity AT mullerjohannes aptamersagainstcovid19anuntestedopportunity |